print version 

Find company
Home About the ProjectContact usFor the Clients
Enter code or ISIN
 
alpha / industry search

Issuers' Corner
Press Releases
Annual Reports Library

Financial Statements
SEC & FFMS Filings
Corporate Presentations
GM Materials
Issues Documents
Corporate Governance Materials
Russian Company Guide
Company Profiles
Corporate Calendar
Markets Corner
Consensus Estimates
Media Corner
News Line


Get updates



Home  Issuers' Corner  Press Releases REGISTER LOG IN

Press Releases

company search
all press releases
all Pharmstandard press releases

Pharmstandard

July 24, 2014

OJSC Pharmstandard and Millhouse completed the Acquisition of Stakes in Biocad Holding Ltd.

Moscow, 24 July, 2014– OJSC Pharmstandard (LSE: PHST IL, RTS: PHST RU) (“Pharmstandard”) and Millhouse LLC (“Millhouse”) today announced they have completed individual acquisitions of stakes in Biocad Holding Ltd., the main shareholder in Russian biotechnological company CJSC Biocad (“Biocad”). 

Biocad specializes in the development, production and promotion of original and generic drugs in the following therapeutic categories: urology, gynecology, dermatovenerology, oncology, hematology, autoimmune and infectious diseases. 

Under the terms of the deal, Pharmstandard acquired 20% of Biocad Holding, while a Millhouse-affiliated entity purchaseâa further 50% stake. 

Pharmstandard financed the acquisition with its own funds. 

“Biotechnology in medicine is one of the most popular investment trends nowadays”, said Pharmstandard CEO Igor Krylov. “In Russia Biocad is undoubtedly a leader in biotechnology industry and now has become a respected partner for us to explore many biopharmaceutical opportunities”. 

Millhouse and Pharmstandard have a successful track record of working together to develop leaders in the pharmaceutical market. The companies previously cooperated on the acquisitions of ICN Pharmaceuticals, Inc. and CJSC Masterlek, and on Pharmstandard’s initial public offering. 

The remaining 30% of Biocad Holdings is controlled by Dmitri Morozov, CEO and founder of Biocad, who will continue to run the company together with his top-notch management team. 

*** 

Contacts:

 

Irina Bakhturina

Head of Investor Relations

OJSC Pharmstandard

Tel.: +7 (495) 970-0030 Ext.2824

Fax: +7 (495) 970-0032

 

John Mann, Anna Sulimina

Information Policy Department

Millhouse LLC

Tel.: +7 (495) 961-1307

Fax: +7 (495) 961-1308

a.sulimina@millhouse.ru

 

 

 

Search by industry

Agriculture, Foresty and Fishing | Chemicals | Engineering | Ferrous Metals | Financial, Insurance & Real Estate | Food & Kindred Products | General Construction | Information Technology | Media & Publishing | Non-Ferrous Metals | Oil & Gas | Pharmaceuticals | Power Industry | Precious Metals and Diamonds | Telecommunications | Transportation | Wholesale & Retail Trade

Search by alpha index

A B C D F G H I K L M N O P R S T U V W X Z


Site Map
© RUSTOCKS.com
Privacy Statement | Disclaimer